EOLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evolus Inc (EOLS) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak technical indicators, insider selling, and declining financial performance despite revenue growth. Analysts have lowered price targets, and trading sentiment is neutral. Given the lack of positive catalysts and the investor's preference for long-term stability, it is best to hold off on investing in this stock.
The stock exhibits bearish technical indicators. The MACD is below 0 and negatively contracting, RSI is neutral at 50.989, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 3.918, and resistance is at 4.338. The stock has a 70% chance of declining in the short term.
Revenue increased by 14.38% YoY in Q4 2025, and gross margin improved slightly to 63.64%.
Insiders are selling heavily, with a 770.69% increase in selling activity over the last month. Net income and EPS have significantly declined (-101.91% and -100.00% YoY, respectively). Analysts have lowered price targets, citing challenges in the aesthetic injectables market.
In Q4 2025, revenue grew by 14.38% YoY to $90.3M. However, net income dropped by -101.91% YoY to $130K, and EPS fell to 0 (-100.00% YoY). Gross margin improved slightly to 63.64%.
Analysts have recently lowered price targets: Mizuho reduced the target from $19 to $15, and BTIG reduced it from $18 to $13. Both maintain positive ratings (Outperform and Buy, respectively) but have adjusted expectations due to market challenges.
